Overview
Cognito Therapeutics is developing non-invasive sensory stimulation therapies using 40Hz gamma frequency light and sound to target the neurological mechanisms underlying Alzheimer's disease. Their OVERTURE Phase 3 clinical trial is evaluating the Cognito Therapy System for slowing cognitive and functional decline in mild-to-moderate Alzheimer's patients.
More in Cognitive Health
Latest industry news
It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments
2026-06-23 · Product
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
2026-06-13 · Research
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
2026-06-11 · Product
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
2026-06-09 · Industry
Company details
Category
💭 Cognitive Health
Location
Cambridge, MA, USA
Funding
Series C · $73M+
Website
cognitotx.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →